Phase 3 Trials Examine Gantenerumab for Early Alzheimer Disease
February 20th 2024Two phase 3 trials were conducted to assess the clinical and biological effects as well as the safety of gantenerumab in individuals with mild cognitive impairment or mild dementia due to AD. Here's what you need to know.
Efficacy Studies of Semaglutide for Type 2 Diabetes Mellitus
February 13th 2024One meta-analysis that included data from 6 placebo-controlled and 7 active-controlled studies using subcutaneous semaglutide found that when compared with placebo, subcutaneous semaglutide 0.5 mg and 1 mg reduced hemoglobin A1c (HbA1c) by 1.01% and 1.38%, respectively.
Different Strokes: How to Spot and Treat Poststroke Depression
May 20th 2021Available evidence indicates that there are a multitude of neuropsychiatric syndromes that occur after a stroke. Cognitive impairment occurs in approximately one-third of patients. These neuropsychiatric manifestations often impede the recovery of motor functioning, reduce social functioning, and decrease the overall quality of life.
8 Neuropsychiatric Symptoms and Treatments of Huntington Disease
March 25th 2021In approximately half of patients with Huntington disease, symptoms of depression, irritability/aggression, executive dysfunction, psychosis, cognitive decline, and dementia present long before progressive motor symptoms.
5 Steps to Improve Outcomes in Substance Abuse in Older Patients
August 3rd 2020Addiction among older adults is associated with worse medical outcomes and increased economic burden of care. The long-term use of psychoactive substances can result in adverse neurological outcomes even at therapeutic doses.